| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/08/2014 | CN102264366B Composition containing sesamins and epigallocatechin gallate |
| 01/08/2014 | CN102234295B Platinum (II) complex adopting N-alkyl substituted trans 1,2-diaminocyclohexane as ligand and preparation method thereof |
| 01/08/2014 | CN102199608B Efficient expression of pinellia ternate agglutinin (PTA) in bombyx mori reactor |
| 01/08/2014 | CN102105474B Purine PI3K inhibitor compounds and methods of use |
| 01/08/2014 | CN102018714B Formulations |
| 01/08/2014 | CN101932939B Marker for determination of sensitivity to anti-cancer agent |
| 01/08/2014 | CN101903349B 4-(4-pyridinyl)-benzamides and application thereof as ROCK activity modulators |
| 01/08/2014 | CN101638414B Peptidyl boronic acid, ester compound thereof, preparation method of peptidyl boronic acid and ester compound thereof, and use of peptidyl boronic acid and ester compound thereof |
| 01/08/2014 | CN101541781B Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
| 01/08/2014 | CN101484467B Method for synthesizing thymosins |
| 01/08/2014 | CN101426772B Benzotriazine inhibitors of kinases |
| 01/07/2014 | US8623881 Inhibitors of human phosphatidylinositol 3-kinase delta |
| 01/07/2014 | US8623870 Pyridazinone derivatives |
| 01/07/2014 | US8623868 Processes of making and using pharmaceutical formulations of antineoplastic agents |
| 01/07/2014 | US8623833 Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| 01/07/2014 | US8623644 Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| 01/07/2014 | US8623643 Antisense oligonucleotide modulation of STAT3 expression |
| 01/07/2014 | US8623431 Composition to enhance the bioavailability of curcumin |
| 01/07/2014 | US8623378 Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof |
| 01/07/2014 | US8623373 Compositions and methods for treatment of angiogenesis in pathological lesions |
| 01/07/2014 | CA2635903C Bisnaphthalimidopropyl derivative compounds with anti-parasite and anti-cancer activity |
| 01/07/2014 | CA2602800C Pyrazolopyridines and analogs thereof |
| 01/07/2014 | CA2542504C Lipids containing omega-3 and omega-6 fatty acids |
| 01/07/2014 | CA2492472C Use of urease for inhibiting cancer cell growth |
| 01/07/2014 | CA2461372C Dna sequences for human angiogenesis genes |
| 01/07/2014 | CA2453967C Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/07/2014 | CA2427896C Carrier vectors through an epithelium with tight junctions |
| 01/07/2014 | CA2318405C Antibodies to death receptor 4(dr4) and uses thereof |
| 01/07/2014 | CA2286798C Alpha-o-linked glycoconjugates with clustered(2,6)-st epitopes, methods of preparation and uses thereof |
| 01/03/2014 | WO2014004902A2 Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof |
| 01/03/2014 | WO2014004854A1 Induction of estrogen receptor beta by cholesterol biosynthesis inhibitors and methods of treatment of cancer |
| 01/03/2014 | WO2014004543A1 Combination cancer therapy using bisphosphonates and anti-egfr agents |
| 01/03/2014 | WO2014004054A1 Compositions and methods for treating cancer with aberrant lipogenic signaling |
| 01/03/2014 | WO2014003830A1 Particle-nucleic acid conjugates and therapeutic uses related thereto |
| 01/03/2014 | WO2014003541A1 Copper(ii) -mixed ligand complexes with anticancer properties |
| 01/03/2014 | WO2014003537A1 Anticancer treatment |
| 01/03/2014 | WO2014003536A1 Dosage regime of fusion compounds |
| 01/03/2014 | WO2014003411A1 Method for preparing α-crystalline form of imatinib mesylate |
| 01/03/2014 | WO2014003098A1 Tricyclic compound |
| 01/03/2014 | WO2014002967A1 4,6-hexadecadiene-2,4-dicarboxylic acid derivative |
| 01/03/2014 | WO2014002922A1 Method for treating cancer by combined use of anti-cancer agent |
| 01/03/2014 | WO2014002836A1 Egfr-binding peptide |
| 01/03/2014 | WO2014002104A1 A synergistic pharmaceutical composition useful for the treatment of lung cancer |
| 01/03/2014 | WO2014002101A1 Lim kinase inhibitors |
| 01/03/2014 | WO2014001802A1 2-aminopyrazine derivatives as csf-1 r kinase inhibitors |
| 01/03/2014 | WO2014001562A1 Lkb1 as predictive marker of everolimus efficacy in breast cancer |
| 01/03/2014 | WO2014001377A1 5-azaindazole compounds and methods of use |
| 01/03/2014 | WO2014001356A1 Method of treating lymphoma using thienotriazolodiazepine compounds |
| 01/03/2014 | WO2014001247A1 N-[4-(Quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products |
| 01/03/2014 | WO2014001183A1 Pharmaceutical composition having synergistic action of direct catalase inhibitors and modulators of no metabolism or of extracellular superoxide anion production which lead to catalase destruction |
| 01/03/2014 | WO2014000713A1 NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS |
| 01/03/2014 | WO2014000686A1 Pyrimidobenzoazepine compound and use thereof as antitumour drug |
| 01/03/2014 | WO2014000586A1 Phenanthroindolizidine alkaloid derivates and salt thereof as well as preparation, plant-virus resisting activity, and anti-cancer activity of phenanthroindolizidine alkaloid derivates and salt thereof |
| 01/03/2014 | WO2014000452A1 Traditional chinese medicine compound gel for external treatment of cancer pain and preparation method for same |
| 01/03/2014 | WO2014000418A1 Cyclopropanecarboxamido-substitute aromatic compounds as anti-tumor agents |
| 01/03/2014 | WO2014000338A1 Application of composite of anti-cd146 antibody and anti-vegf antibody in preparing medicine for suppressing tumor |
| 01/03/2014 | WO2014000032A1 Phenyl amino pyrimidine bicyclic compounds and uses thereof |
| 01/03/2014 | WO2014000027A1 Prevention and treatment of haematological conditions |
| 01/03/2014 | WO2013166004A3 Organic compositions to treat kras-related diseases |
| 01/03/2014 | WO2013158717A3 Compositions comprising an internalizing nucleic acid molecule, and their methods of use |
| 01/03/2014 | WO2013156861A3 Methods and compounds for treating proliferative disorders and viral infections |
| 01/03/2014 | WO2013140319A9 Crystalline form of a succinate salt |
| 01/03/2014 | WO2009158026A9 Hydrazonamide compounds that modulate hsp90 activity |
| 01/03/2014 | CA2878049A1 Novel fused pyridine derivatives useful as c-met tyrosine kinase inhibitors |
| 01/03/2014 | CA2877968A1 Methods and compositions for natural killer cells |
| 01/03/2014 | CA2877923A1 Phenyl amino pyrimidine bicyclic compounds and uses thereof |
| 01/03/2014 | CA2877786A1 N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products |
| 01/03/2014 | CA2877449A1 2-aminopyrazine derivatives as csf-1 r kinase inhibitors |
| 01/03/2014 | CA2877434A1 Method of treating lymphoma using thienotriazolodiazepine compounds |
| 01/03/2014 | CA2877378A1 Methods of treating breast cancer with gemcitabine therapy |
| 01/03/2014 | CA2877272A1 Dosage regime of fusion compounds |
| 01/03/2014 | CA2876241A1 Induction of estrogen receptor beta by cholesterol biosynthesis inhibitors and methods of treatment of cancer |
| 01/03/2014 | CA2876165A1 Particle-nucleic acid conjugates and therapeutic uses related thereto |
| 01/02/2014 | US20140005256 Formulations with anti-tumour action |
| 01/02/2014 | US20140005156 Aminoalkylsterol compounds with antitumoral and neuroprotective activity |
| 01/02/2014 | US20140004113 Defensin-antigen fusion proteins |
| 01/02/2014 | US20140004095 Albumin fusion proteins |
| 01/02/2014 | US20140004089 Chimeric glycoproteins and pseudotyped lentiviral vectors |
| 01/02/2014 | US20140004078 Immunoconjugates with an Intracellularly-Cleavable Linkage |
| 01/02/2014 | US20140004077 Method for treating cervical cancer |
| 01/02/2014 | US20140004037 Stabilization of the anti-cd20 antibody rituximab |
| 01/01/2014 | EP2679681A1 Fc riib-specific fc antibody |
| 01/01/2014 | EP2679599A1 Antibodies directed to Angiopoietin-1 and Angiopoietin-2 and use thereof |
| 01/01/2014 | EP2679595A2 Di-(3-deoxy-3-1H-1,2,3-triazol-1-yl)-[beta]-D-galacto-pyranosyl)sulfane |
| 01/01/2014 | EP2679574A1 Hydrated n-fullerene amino acids, method for producing the latter, and pharmaceutical compositions on the basis thereof |
| 01/01/2014 | EP2679247A1 Carboxylic mannan-coated contrast agent for magnetic resonance imaging |
| 01/01/2014 | EP2679225A1 Pharmaceutical compound with synergistic effect of direct catalase inhibitors and modulators for NO metabolism which lead to catalase destruction or extracellular superoxide anion production |
| 01/01/2014 | EP2678447A1 Cancer diagnosis and treatment |
| 01/01/2014 | EP2678341A1 Alpha helix mimetics and methods relating thereto |
| 01/01/2014 | EP2678337A1 2-amino-naphthyridine derivatives |
| 01/01/2014 | EP2678336A1 Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors |
| 01/01/2014 | EP2678316A2 Substituted aromatic sulfur compounds and methods of their use |
| 01/01/2014 | EP2678075A1 Solid forms of a pharmaceutically active substance |
| 01/01/2014 | EP2678042A2 Amphiphilic dendron-coils, micelles thereof and uses |
| 01/01/2014 | EP2678039A1 Bisphosphonate-prodrugs |
| 01/01/2014 | EP2678034A2 Anti-endoglin antibodies and knockin mice expressing novel human/mouse chimeric endoglin |
| 01/01/2014 | EP2678021A2 Phosphorus containing compounds as protein kinase inhibitors |
| 01/01/2014 | EP2678014A2 Prostate cancer therapy with hsp90 inhibitory compounds |
| 01/01/2014 | EP2678013A1 Combination therapy of hsp90 inhibitory compounds with radiotherapy |
| 01/01/2014 | EP2678012A1 C-glucosidic ellagitannin compounds for use for altering the supramolecular arrangement of actin and for the treatment of osteoporosis, cancer, bacterial infection and viral infection |